BDKRB2+9/-9 Polymorphism Is Associated with Higher Risk for Diabetes Mellitus in the Brazilian General Population
Carregando...
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
HINDAWI PUBLISHING CORPORATION
Autores
NASCIMENTO, Raimundo M.
COELHO, George L. L. M.
MILL, Jose G.
Citação
EXPERIMENTAL DIABETES RESEARCH, article ID 480251, 4p, 2012
Resumo
Some mechanisms have been proposed to explain the role of bradykinin on glucose homeostasis and some studies reported that the BDKRB2 +9/-9 polymorphism was associated to the transcriptional activity of the receptor. In this scenario, the main aim of this study was to evaluate the association of the BDKRB2 +9/-9 polymorphism with diabetes mellitus risk in the Brazilian general population. This study included 1,032 subjects of the general urban population. Anthropometrical, blood pressure, biochemical, and genotype analyses for the BDKRB2 +9/-9 bp insertion/deletion polymorphism were performed. Individuals carrying +9/+9 or +9/-9 genotypes had higher glucose values (84.5 mg/dL versus 80.6 mg/dL, resp.) and higher frequency of diabetes mellitus (7.6% versus 3.6%, resp.) compared to individuals carrying -9/-9, adjusting for age and gender. In addition, higher diabetes mellitus risk was associated to presence of the +9/+9 or +9/-9 genotypes (OR = 1.91; 95% CI = 1.09-4.19; P = 0.03). Our data suggest that the BDKRB2 +9/-9 polymorphism may act as a genetic modulator of glucose homeostasis. It was previously associated to insulin sensitivity, glucose uptake, and insulin secretion, and, in this study, data suggest that the polymorphism may increase susceptibility to chronic metabolic conditions such as diabetes in the Brazilian population.
Palavras-chave
Referências
- Alvim RO, 2012, J HUM HYPERTENS, V26, P340, DOI 10.1038/jhh.2011.102
- BECKNIELSEN H, 1994, J CLIN INVEST, V94, P1714, DOI 10.1172/JCI117518
- Braun A, 1996, IMMUNOPHARMACOLOGY, V33, P32, DOI 10.1016/0162-3109(96)00079-3
- Doetze G., 1977, FEBS LETT, V74, P205
- Duka I, 2001, HYPERTENSION, V38, P1355, DOI 10.1161/hy1201.096574
- Henriksen EJ, 1996, DIABETES, V45, pS125
- Iozzo P, 2012, J CLIN ENDOCR METAB, V97, pE1192, DOI 10.1210/jc.2011-3245
- KAMMERER S, 1995, BIOCHEM BIOPH RES CO, V211, P226, DOI 10.1006/bbrc.1995.1800
- Lung CC, 1997, J ALLERGY CLIN IMMUN, V99, P134, DOI 10.1016/S0091-6749(97)81054-8
- Makdisse M, 2008, ARQ BRAS CARDIOL, V91, P370
- REGOLI D, 1980, PHARMACOL REV, V32, P1
- Rocha E.S.M., 1949, AM J PHYSIOL, V156, P261
- Santos PCJL, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-13
- Santos PCJD, 2011, AM J HYPERTENS, V24, P278, DOI 10.1038/ajh.2010.244
- Shiuchi T, 2002, HYPERTENSION, V40, P329, DOI 10.1161/01.HYP.0000028979.98877.0C
- Soares RAG, 2012, GENET TEST MOL BIOMA, V16, P957, DOI 10.1089/gtmb.2012.0019
- UEHARA M, 1994, DIABETOLOGIA, V37, P300, DOI 10.1007/BF00398058
- YANG C, 1995, AM J PHYSIOL-ENDOC M, V268, pE1027
- [Anonymous], 1999, J HYPERTENSION, V17, P151
- [Anonymous], 2011, DIABETES CARE S1, V34, pS4